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Abstract
Background: Galectin-3 (Gal-3) is an anti-apoptotic molecule involved in thyroid cells transformation. It is specifically
overexpressed in thyroid tumour cells and is currently used as a preoperative diagnostic marker of thyroid malignancy. Gal-3
expression is downregulated by wt-p53 at the transcriptional level. In well-differentiated thyroid carcinomas (WDTCs) there
is an unexplained paradoxical concomitant expression of Gal-3 and wt-p53. HIPK2 is a co-regulator of different transcription
factors, and modulates basic cellular processes mainly through the activation of wt-p53. Since we demonstrated that HIPK2
is involved in p53-mediated Gal-3 downregulation, we asked whether HIPK2 deficiency might be responsible for such
paradoxical Gal-3 overexpression in WDTC.
Methodology/Principal Findings: We analyzed HIPK2 protein and mRNA levels, as well as loss of heterozygosity (LOH) at
the HIPK2 locus (7q32-34), in thyroid tissue samples. HIPK2 protein levels were high in all follicular hyperplasias (FHs)
analyzed. Conversely, HIPK2 was undetectable in 91.7% of papillary thyroid carcinomas (PTCs) and in 60.0% of follicular
thyroid carcinomas (FTCs). HIPK2 mRNA levels were upregulated in FH compared to normal thyroid tissue (NTT), while PTC
showed mean HIPK2 mRNA levels lower than FH and, in 61.5% of cases, also lower than NTT. We found LOH at HIPK-2 gene
locus in 37.5% of PTCs, 14.3% of FTCs and 18.2% of follicular adenomas. To causally link these data with Gal-3 upregulation,
we performed in vitro experiments, using the PTC-derived K1 cells, in which HIPK2 expression was manipulated by RNA
interference (RNAi) or plasmid-mediated overexpression. HIPK2 RNAi was associated with Gal-3 upregulation, while HIPK2
overexpression with Gal-3 downregulation.
Conclusions/Significance: Our results indicate that HIPK2 expression and function are impaired in WDTCs, in particular in
PTCs, and that this event explains Gal-3 overexpression typically observed in these types of tumours. Therefore, HIPK2 can
be considered as a new tumour suppressor gene for thyroid cancers.
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Introduction
The family of the Homeodomain Interacting Protein Kinase (HIPK)
genes was discovered thirteen years ago. Their ability to interact
and phosphorylate specific serine/threonine residues in many
different targets and partners has been extensively studied. By
virtue of their protein/protein interaction, HIPKs are involved in
the regulation of gene transcription and in cell response to DNA
damage [1]. HIPK2, the most studied member of the family, acts
as co-regulator of an increasing number of transcription factors
and modulates many different basic cellular processes such as
apoptosis, proliferation, DNA damage response, differentiation,
and development. Most of these effects are mediated by
phosphorylation and activation of the oncosuppressor protein
p53 [2–5]. However, the exact role of HIPK2 in the development
and progression of human cancer is not clear yet. Recently, two
missense mutations of the HIPK2 gene have been identified in
acute myeloid leukaemia (AML) and in myelodysplastic syndrome
(MDS), a pre-leukaemia syndrome [6]. However, extensive search
failed to detect any mutation in many other tumours. An
alternative mechanism of HIPK2 inactivation, described in breast
cancer, is its cytoplasmic relocalization mediated by the interaction
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20665with HMGA1 that causes inhibition of nuclear activation of wt-
p53 apoptotic function [7]. Experiments performed in normal rat
thyroid epithelial PC Cl3 cells demonstrated that HIPK2 exerts a
potent inhibitory effect on cell growth, and this effect is mediated
by its kinase activity [8]. In another preliminary study, HIPK2 gene
expression was analyzed in a panel of 14 thyroid carcinomas and a
3 to 10-fold reduction in its mRNA expression levels was observed
in 8 of them [9]. Recently, we demonstrated that HIPK2 is
involved in the p53-mediated repression of the anti-apoptotic
factor Galectin-3 (Gal-3) [10]. Gal-3 is a b-galactoside-specific
lectin with anti-apoptotic activity, involved in both tumourigenesis
and resistance to chemotherapeutic drugs [11–12]. Gal-3 posses
the functional BH1 domain of the Bcl-2 family [13], inhibits
cytochrome-c release from mitochondria [14], and is aberrantly
expressed in different types of human cancers [15]. In vitro
experiments demonstrated that Gal-3 expression is required for
the maintenance of the transformed phenotype of papillary thyroid
carcinoma (PTC)-derived cells [16] and is responsible for
chemoresistance and refractoriness to conventional treatments of
PTCs [17]. In vivo studies, performed on well differentiated
(WDTCs) and anaplastic thyroid tumours (ATCs), demonstrated
that Gal-3 expression was restricted to the cytoplasm of malignant
thyroid follicular cells [18,19]. Based on the results of a prospective
multicenter study, Gal-3 overexpression is now considered as a
sensitive marker of thyroid malignancy and it is currently used in
the preoperative diagnosis of thyroid cancer [20]. In our previous
study, we demonstrated that, in poorly differentiated thyroid
carcinomas (PDTCs) and ATCs, the occurrence of a gain-of-
function p53 mutation not only leads to the loss of the capability to
downregulate Gal-3 but it acquires a de novo ability to stimulate its
expression and induce chemoresistance [19]. However, in
WDTCs there is an unexplained paradoxical concomitant
expression of Gal-3 and wt-p53 [21,22]. Since HIPK2 is involved
in p53-mediated Gal-3 downregulation, we asked whether HIPK2
deficiency might be responsible for such paradoxical behaviour. In
the present study we show that: i) HIPK2 protein expression is lost
in PTCs; ii) HIPK2 mRNA levels are up-regulated in follicular
hyperplasia (FH) and reduced in PTC and in follicular variants of
PTC (FVPTC); iii) loss of heterozygosity (LOH) affecting the
HIPK2 gene locus can be detected in more than one third of PTCs;
iv) RNA interference (RNAi) or overexpression of HIPK2 in PTC-
derived K1 cells causes upregulation or downregulation respec-
tively of Gal-3 expression.
Taken together, our results show the loss of the p53 activator
HIPK2 in WDTC and the concomitant upregulation of the anti-
apoptotic factor Gal-3. These results may explain the paradoxical
co-expression of wt-p53 and Gal-3 in these types of tumours and
suggest that HIPK2 can be considered as a tumour suppressor gene
in thyroid cancers.
Results
HIPK2, p53 and Gal-3 protein expression analysis
In order to analyze HIPK2 protein levels in wt-p53-carriyng
WDTCs and to correlate it with Gal-3 protein expression, a total
of 43 thyroid lesions from patients of group A, including 14 FHs,
24 PTCs and 5 follicular thyroid carcinomas (FTCs) (Table 1),
have been analyzed by immunohistochemistry (IHC) for the
expression of HIPK2, p53 and Gal-3 (Table 2).
HIPK2 protein expression analysis revealed a nuclear immuno-
staining in all FHs analyzed (Table 2; Figure 1, panels A, B).
Conversely, HIPK2 was absent in almost all PTC samples; in
particular, 22 out of 24 PTCs analyzed (91.7%) were negative for
HIPK2 immunostaining and the remaining 2 cases (8.3%) showed
expression of HIPK2 in less than 10% of cells (Table 2; Figure 1,
panel B). It is noteworthy that all oncocytic PTC and all FVPTC
samples were negative for HIPK2 protein expression (Table 2;
Figure 1, panel B). Moreover, 3 out of 5 (60.0%) FTCs analyzed were
negative for HIPK2 expression and the remaining two cases (40.0%)
showed HIPK2 immunostaining (Table 2; Figure 1, panel B).
To test if the nuclear clearing observed in PTCs could alter the
immunoreactivity of the nuclear compartment in these specific
tumours, we analyzed the expression of Cyclin D1 by using IHC
[23]. As shown in Figure 1, Cyclin D1 nuclear expression was
sharply detectable in the clear nuclei of PTC cells (Figure 1, panel
A), supporting the fact that lack of HIPK2 immunoreactivity
observed in PTCs is a specific event and it is not due to an artefact.
P53 protein expression was negative in all thyroid samples
analyzed (Table 2). Immunohistochemical p53 negativity is
generally considered indicative of the absence of p53 mutations
[24]. This result suggests that all thyroid lesions analyzed express a
wt-p53, in agreement with previous studies that reported the
occurrence of p53 mutation only in poorly differentiated or in
undifferentiated thyroid carcinomas [21–22].
Immunohistochemical analysis confirmed the lack of Gal-3
expression in all FHs examined, in agreement with the previous
published results [17] (Table 2; Figure 1, panel A). Among
WDTCs, 23 out of 24 PCT (95.8%) and 4 out of 5 FTC (80%)
samples expressed high Gal-3 protein levels (Table 2; Figure 1,
panel B).
Our results indicate the existence of a strong, inverse correlation
between HIPK2 and Gal-3 protein levels. In particular, all FH
samples were positive for HIPK2 and negative for Gal-3 staining,
while most of WDTCs (79.3%) showed overexpression of Gal-3,
associated with the absence of HIPK2 protein expression (Table 2;
Figure 1, panel B). This inverse correlation was even stronger in
FVPTCs, where 9 out of 9 cases (100%) were Gal-3 positive and
HIPK2 negative (Table 2; Figure 1, panel B).
These results show that HIPK2 protein expression is lost in
WDTCs and in particular in PTCs and in FVPTCs. Moreover,
the inverse correlation between HIPK2 and Gal-3 protein levels
suggests that the overexpression of Gal-3 in WDTCs might be
related to the absence of HIPK2.
HIPK2 gene expression analysis
To understand the molecular mechanisms responsible for
HIPK2 protein expression loss in PTCs, we analyzed HIPK2
mRNA levels by TaqMan quantitative RT-PCR in a total of 40
thyroid lesions from patients of group B, including 14 FHs and 26
PTCs. The expression of each sample has been calculated
relatively to that observed in a pool of 10 normal thyroid tissues
(NTT). When compared to the value of 1.0 of the normal pool,
FHs showed a mean HIPK2 expression level of 4.2 (63.4) (Figure 2,
panel A). In PTCs, HIPK2 mRNA levels were significantly lower
than in FH (P,0.005), with a mean level of 1.4 (61.2) (Figure 2,
panel A). Considering only FVPTC samples, HIPK2 mRNA levels
were lower than normal pool with a mean of 0.7 (60.5) (Figure 2,
panel A).
The analysis of the percentage of cases with HIPK2 expression
levels higher or lower than NTT samples demonstrated that in
FH, 11 out of 14 cases (78.6%) had HIPK2 mRNA levels higher
than NTT (Figure 2, panel B). Conversely, 16 out of 26 PTCs
(61.5%) and 7 out of 8 FVPTCs (87.5%) showed HIPK2 mRNA
levels lower than NTT pool (Figure 2, panel B).
These results demonstrate that HIPK2 mRNA levels are
upregulated in FH with respect to NTT. However, PTC showed
mean HIPK2 mRNA expression levels three times lower than FH
and, in the majority of cases, also lower than NTT.
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A
case # age sex diagnosis
13 8 F F H
26 7 M F H
34 6 M F H
43 6 F F H
57 0 F F H
65 1 F F H
76 2 F F H
85 1 F F H
95 0 F F H
10 24 F FH
11 32 F FH
12 63 M FH
13 49 F FH
14 47 M FH
B
case # age sex diagnosis TNM stage size (cm)
15 77 F PTC T3 N1a M0 III 9
16 23 F PTC T1b N1 M0 I 2
17 41 F PTC T3 N1 M0 I 3.2
18 23 F PTC T3 N0 M0 I 2.5
19 35 F PTC T1a N0 M0 I 1
20 27 F PTC T3 N1b M0 I 1
21 20 F PTC T1b N1 M0 I 1.8
22 46 M PTC T3 N0 M0 III 1.5
23 30 M PTC T3 N1b M0 I 4.2
24 56 M PTC T1a N0 M0 I 1
25 26 F PTC T3 N1b M0 I 2.5
26 79 M PTC T3 N0 M0 III 5
27 46 F PTC onco. T1b N0 M0 I 1.7
28 48 F PTC onco. T1a N0 M0 I 0.9
29 32 F PTC onco. T1b N0 M0 I 1.5
30 40 F FVPTC T3 N0 M0 I 4
31 59 F FVPTC T1a N0 M0 I 1
32 60 F FVPTC T3 N0 M0 III 1.5
33 42 F FVPTC T3 N0 M0 I 1.2
34 64 F FVPTC T1a N0 M0 I 1
35 75 F FVPTC T1a N0 M0 I 1
36 73 M FVPTC T1a N0 M0 I 2
37 66 F FVPTC T3 N1b M0 IV A 3.8
38 36 F FVPTC T1b N0 M0 I 1.2
39 55 F FTC T1b N0 M0 I 2
40 28 M FTC T3 N0 M0 I 4.5
41 21 F FTC T2 N0 M0 I 3.4
42 63 F FTC onco. T2 N0 M0 II 3.3
43 81 F FTC onco. T3 N0 M0 III 8
Patients were divided, according to histological diagnosis, in FHs (A) and WDTCs (B).
doi:10.1371/journal.pone.0020665.t001
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Allelic loss at the long arm of chromosome 7, where the HIPK2
gene is located, is a frequent event in PTC [25–27]. Thus, we
tested whether one of the mechanisms of loss of HIPK2 expression
observed in WDTCs might be the loss of genetic material at the
HIPK2 gene locus. We performed LOH analysis at 7q32-34 in 61
patients from group C, including 32 PTCs, 22 follicular adenomas
(FAs) and 7 FTCs. Gal-3 expressing tumour cells and matching
extra-tumour thyroid follicular cells were selectively isolated by
Laser Capture Microdissection (LCM) (Figure 3, panel A). LOH
analyses were performed at a microsatellite marker (D7S2468),
proximal to the HIPK2 gene (Figure 3, panels B, C) and at a new
microsatellite marker (D7S6440) internal to the HIPK2 gene that
we identified in a non-coding region of intron 9 (Figure 3, panel
B). We found LOH in 10 out of 30 informative cases (33.3%) at
the proximal marker, and in 12 out of 32 informative cases
(37.5%) at the internal marker (Figure 4, panels A, B). LOH at
both microsatellite markers was detected in 8 cases and the
frequency of allelic loss was higher in the HIPK2-internal
microsatellite, indicating that the HIPK2 gene is located inside
the smallest common deleted region. We found LOH for the
microsatellite marker D7S6440 in 4 out of 22 (18.2%) FAs and in 1
out of 7 (14.3%) FTC cases (Figure 4, panels A, B). As further
control, a portion of the coding region (exon 2) of the HIPK2 gene
was amplified on DNA extracted from microdissected cells.
Densitometric analyses of the relative bands showed 50% intensity
reduction only in patients with LOH (Figure 3, central panel C)
indicating the occurrence of a deletion including at least part of the
HIPK2 gene.
Thus, loss of one copy of the HIPK2 gene is a relatively
common event in PTC that may partially contribute to the
decrease of HIPK2 mRNA and protein expression levels observed
in PTCs.
Effects of modulation of HIPK2 protein levels on Gal-3
expression
To demonstrate that Gal-3 overexpression in WDTCs is a
consequence of HIPK2 protein loss, we modulated HIPK2
expression levels in vitro by RNAi or by vector-mediated
overexpression in a wt-p53-carring PTC-derived cell line, namely
the K1 cells (ECACC, Salisbury, United Kingdom). Stable RNAi
of HIPK2 expression in K1 cells induced upregulation of Gal-3
both at the protein (Figure 5, panel A) and mRNA (Figure 5, panel
B) levels. Conversely, overexpression of HIPK2 in the same cells
caused a concomitant downregulation of Gal-3 protein (Figure 5,
panel C) and mRNA (Figure 5, panel D) levels. Moreover,
overexpression of the HIPK2 kinase-dead mutant K221R, in K1
cells was unable to phosphorylate p53 on Ser46 and to
downregulate Gal-3 expression levels compared to wt-HIPK2
(Figure 5, panel E). These results demonstrate that Gal-3 protein
levels are regulated by HIPK2 expression and kinase activity
probably through the specific phosphorylation of p53 protein at its
residue Ser46. These data reinforce our hypothesis that the loss of
Table 2. HIPK2, p53 and Gal-3 protein expression analysis in
thyroid tumours by IHC.
Case # HIPK2 p53 Gal-3
Follicular Hyperplasia (FH)
1 + Neg. Neg.
2 + Neg. Neg.
3 + Neg. Neg.
4 + Neg. Neg.
5 + Neg. Neg.
6 +/2 Neg. Neg.
7 + Neg. Neg.
8 + Neg. Neg.
9 + Neg. Neg.
10 + Neg. Neg.
11 + Neg. Neg.
12 + Neg. Neg.
13 + Neg. Neg.
14 + Neg. Neg.
Papillary Thyroid Carcinoma (PTC)
15 Neg. Neg. ++
16 Neg. Neg. ++
17 +/2 Neg. ++
18 Neg. Neg. ++
19 Neg. Neg. ++
20 Neg. Neg. ++
21 +/2 Neg. ++
22 Neg. Neg. ++
23 Neg. Neg. ++
24 Neg. Neg. ++
25 Neg. Neg. ++
26 Neg. Neg. ++
Oncocytic PTC
27 Neg. Neg. Neg.
28 Neg. Neg. ++
29 Neg. Neg. ++
Follicular Variant of PTC (FVPTC)
30 Neg. Neg. +
31 Neg. Neg. ++
32 Neg. Neg. ++
33 Neg. Neg. ++
34 Neg. Neg. ++
35 Neg. Neg. ++
36 Neg. Neg. +/2
37 Neg. Neg. ++
38 Neg. Neg. ++
Follicular Thyroid Carcinoma (FTC)
39 Neg. Neg. ++
40 Neg. Neg. +/2
41 Neg. Neg. Neg.
Oncocytic FTC
42 +/2 Neg. ++
43 + Neg. +
Expression analysis of HIPK2, p53 and Gal-3 in thyroid lesions of group A with
the indicated origin, using biotin-free IHC. Results are expressed as: Neg when
no immunostaining was observed, +/2 when immunostaining was restricted to
less than 10% of malignant cells, + when positivity was seen in 10%–70% of
cells, and ++ when more than 70% of malignant cells was positive to
immunostaining.
doi:10.1371/journal.pone.0020665.t002
Table 2. Cont.
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the concomitant overexpression of Gal-3.
Discussion
Ionizing radiation has been known for a number of years to be
associated with an increased risk of developing a thyroid
carcinoma. Exposure to radiation, either from the environment
or as a result of medical treatments, in particular when radiation is
applied to the head and neck region, represents the most common
cause of thyroid cancer [28–30]. The reason why thyroid cancer is
so sensitive to the effects of radiations is not known. The apoptotic
pathway triggered by DNA damage is a relevant major target in
thyroid cancer tumourigenesis. We recently identified some of the
major components of this pathway. In particular, we demonstrated
that DNA damage induced by UV irradiation is responsible for the
Figure 1. Inverse correlation between HIPK2 and Gal-3 expression in WDTCs. (A) Representative immunohistochemical analysis of HIPK2,
Gal-3 and Cyclin D1 in PTC. Arrows indicate positive immunostaining for HIPK2 (upper panel) and Cyclin D1 (lower, right panel) into the nuclear
compartment of respectively normal and papillary thyroid cells. In the lower left panel is clearly visible cytoplasmic expression of Gal-3 in tumoural
tissue. (B) The histogram shows, for each histotype, the percentage of positive cases at the immunohistochemical expression analysis for HIPK2 (white
bars) and Gal-3 (black bars).
doi:10.1371/journal.pone.0020665.g001
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phosphorylation of specific serine/threonine residues in p53
protein. Finally, phosphorylated p53 protein induces downregu-
lation of the potent anti-apoptotic molecule Gal-3, by repressing its
expression directly at the promoter level. The decrease in Gal-3
mRNA and protein levels facilitates the occurrence of apoptosis
[10]. We then demonstrated that in highly aggressive thyroid
tumours, characterized by the occurrence of p53 mutations, this
pathway is disregulated. UV-induced damage in cells bearing a
mutated p53, in fact, not only is no longer able to repress Gal-3,
but it exerts a stimulatory effect on Gal-3 expression. Mutant p53-
induced Gal-3 overexpression may explain the aggressive
phenotype and chemoresistance, typically encountered in ATCs
or PDTCs [19]. Therefore, we proposed a model in which the
thyroid cells, exposed to radiations, activate the apoptotic pathway
HIPK2/wtp53/Gal-3, which physiologically regulates the fate of
damaged cells. However, when a gain-of-function p53 mutation
occurs, HIPK2/mutp53/Gal-3 axis is no longer protective against
the development of cancer and becomes responsible for the
acquisition of new additional tumorigenic properties. The weak
and unexplained point of this model relies in the paradoxical
behaviour of wt-p53 and Gal-3 in WDTCs. It is well documented
that such tumours express a wt-p53 and, in the present study, we
found undetectable immunohistochemical levels of p53, generally
considered as a surrogate of the absence of p53 mutations [24]. In
agreement with our model, the presence of a wt-p53 should exert
its repressive effect on Gal-3 expression. On the contrary, Gal-3 is
highly expressed in WDTCs and, this feature, is so sensitive and
specific that it is used as preoperative diagnostic marker [18,20].
To explain this paradoxical behaviour we postulate that in WDTC
wt-p53 protein is inactive because of a yet-to-be-discovered
alteration in the upstream mechanisms responsible for its post-
transcriptional modifications (acetylation and/or phosphoryla-
tion). Phosphorylation, in fact, is a key event in p53 activation and
induction of apoptosis [2–3]. We focused our attention on HIPK2,
one of the major p53 activators, but we cannot exclude that other
p53 activators may be involved as well. In this study we
demonstrate the loss of HIPK2 in WDTCs, using three different
methods, and by analyzing three independent groups of patients.
In particular, we analyzed HIPK2 protein expression by IHC in
thyroid histological slides, HIPK2 mRNA expression by Real Time
RT-PCR on total RNA extracted from frozen thyroid tissues
samples, and genetic loss at HIPK2 locus, by LOH analysis in
thyroid cancer cells, stained with Gal-3, and retrieved by LCM.
We found undetectable or very low levels of HIPK2 protein
expression in all tumour samples analyzed. HIPK2 mRNA was
Figure 3. LOH analysis of HIPK2 gene locus 7q32-34 in WDTCs. (A) Histological pictures of PTC and its matching extra-tumour thyroid tissue
immunostained for Gal-3. The upper right panel shows the histological area subjected to laser-based microdissection. (B) Schematic representationo f
chromosome 7, HIPK2 locus, and regions including the two microsatellite markers and one HIPK2 exon amplified by PCR in cells dissected as in (A).
The microsatellite amplification products (left and right panels) were resolved onto 12% PAGE and visualized by silver staining. The arrows indicate
the missing bands diagnostic of LOH. Quantitative PCR products amplified with the indicated exon 2 primers were resolved and stained as above
(central panel).
doi:10.1371/journal.pone.0020665.g003
Figure 2. HIPK2 mRNA expression analysis in WDTCs. (A) Real Time RT-PCR analysis of HIPK2 gene expression in 48 surgical samples of group B
patients. Mean HIPK2 mRNA levels 6 SD are shown for FHs, PTCs, and FVPTCs. The results, calculated with 2
DDCT method, are expressed relatively to
the value of 1.0 obtained analyzing a pool of 10 mRNA extracted from NTT. Horizontal bars indicate the average score within each group of samples,
while boxes indicate 6SD. (B) The histogram shows the percentage of samples, within each indicated histotype, with HIPK2 mRNA expression levels
higher (white bars) or lower (black bars) compared to that obtained in the pool of NTT.
doi:10.1371/journal.pone.0020665.g002
HIPK2 Loss in Thyroid Tumours
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20665reduced, compared to normal tissue, in 61.5% of PTCs and in
87.5% of FVPTCs. Interestingly, HIPK2 decreased expression at
mRNA and protein level was observed in all the cases of FVPTCs,
suggesting a relevant role of HIPK2 in this tumour type. In this
study we report, for the first time, the occurrence of HIPK2 mRNA
overexpression in almost all FHs analyzed. Mean mRNA levels
were more than four times higher compared to NTT. This result is
in agreement with previous observation reported in hematopoietic
and skeletal muscle cells, where HIPK2 expression was increased
upon stimulation of cell proliferation, under physiological
conditions [31].
The concordance between HIPK2 loss and Gal-3 overexpres-
sion was not observed in only two cases (see Table 2). The
occurrence of WDTCs characterized by the absence of Gal-3
expression is rather uncommon and it might be related to the
occurrence of a more aggressive phenotype [32–36]. We do not
know the reason why Gal-3 is not expressed in these lesions and do
not have any data so far. We can only speculate that a yet-to-be-
discovered specific genetic damage might affect LGALS3 gene. It is
interesting to note that HIPK2 loss appears to be correlated to the
presence of malignancy with more sensitivity, compared to Gal-3
overexpression. However, in four cases HIPK2 was detectable, at
low level, in the presence of Gal-3 overexpression, indicating that
mechanisms that do not imply HIPK2 downregulation, but affect
its activity or sub-cellular localization, could be involved in thyroid
tumourigenesis [7]. One may hypothesize that the combination of
analysis of these two protein markers, namely HIPK2 and Gal-3,
would be helpful in ameliorating the preoperative recognition of
thyroid cancer.
Finally, allelic loss at the HIPK2 gene locus was found in 37.5%
of PTCs. Therefore, we may speculate that genetic events, leading
to loss of one allele at the HIPK2 gene locus, may account for more
than one third of the cases. In this regard, it is relevant to note that
the HIPK2 gene locus is located in a region where the presence of
fragile sites has been reported [36–38]. It is likely that other events,
either at the transcriptional and post-transcriptional or at the
translational and post-translational levels may explain why HIPK2
mRNA and protein are lost, in the absence of LOH.
Figure 4. Analysis of allelic loss affecting HIPK2 gene in WDTCs. (A) Results of LOH analysis at the indicated loci and microsatellite markers in
32 PTCs, 22 FAs and 7 FTCs of group C patients. For each case the retention of heterozigosity (empty box), the LOH (half-filled box), the non-
informative condition (NI) as well as the FAL index are reported. PTC cases showing LOH at both microsatellites are highlighted in boxes. (B) The
histogram shows the percentage of LOH in each indicated histotype, evaluated at the two microsatellites, namely D7S2469 (white bar) and D7S6440
(black bars).
doi:10.1371/journal.pone.0020665.g004
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expression in WDTC and indicates that such event may be
responsible for lack of p53 activation, thus explaining the
paradoxical co-expression of a wt-p53 and overexpressed Gal-3.
HIPK2 may represent a new tumour suppressor gene for these
types of cancers and may constitute a new potential promising
diagnostic marker and therapeutic target.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki and was approved by the following
Ethics Committees: Ethics Committee of St. Andrea Universitary
Hospital, Rome, Italy; Ethics Committee of Policlinico Umberto I
Universitary Hospital, Rome, Italy; Ethics and Scientific Com-
mittee of Policlinico ‘‘G. Martino’’ Universitary Hospital, Messina.
Italy.
All patients provided written informed consent for the collection
of samples and subsequent analyses.
Thyroid tissue specimen collection
Thyroid tissue samples were collected at three different Italian
Universitary Hospitals, namely St. Andrea and Policlinico
Umberto I, in Rome and Policlinico ‘‘G Martino’’, in Messina.
Tissue samples were obtained at surgery, according to local ethical
committee. Histological diagnoses were rendered in agreement
with WHO guidelines [39], and according to the recently
published new criteria [40]. In this study three different and
independent groups of thyroid tissue specimens were analyzed:
group A, composed of 14 FHs, 24 PTCs and 5 FTCs, was
analyzed by IHC (Table 1); group B, composed of 10 NTTs, 14
FHs and 26 PTCs, was analyzed by Real Time RT-PCR; group
C, composed of 32 PTCs, 7 FTCs and 22 FAs, was subjected to
LOH analysis performed on cells isolated by means of the LCM.
Immunohistochemical analysis
Formalin-fixed and paraffin-embedded tissue specimens were
used to prepare serial tissue sections for conventional morphologic
evaluation and immunophenotypical assay. HRP-conjugated rat
mAb to Gal-3 (Galectin-3 thyrotest – Space Import-Export S.r.l.
Milan, Italy), mouse mAbs to p53 and Cyclin D1 (Dako), and
polyclonal antisera to HIPK2 [31] were used in IHC as previously
described [18]. Antigen retrieval microwave treatment of tissues
slides in 0.01 mol/l citrate buffer pH 6.0 was applied as required.
HRP-conjugated goat anti-mouse or anti-rabbit immunoglobulins
(Dako) were used as secondary antisera for p53, cyclin D1 and
HIPK2 immunostaining respectively, in indirect immunoperox-
idase assay. IHC evaluation was performed independently by two
experienced pathologists.
RNA extraction and semiquantitative RT-PCR analysis
RNA extraction and cDNA synthesis were performed as
previously described [10]. PCR amplifications were run using
2 ml of cDNA template with an initial denaturation step of 94uC
for 5 min followed by 24–30 cycles at 94uC for 1 min, 55uC for
1 min, 72uC for 1 min, and a final extension cycle at 72uC for
7 min. The 18S RNA was used to normalize the amount of total
Figure 5. Effects of modulation of HIPK2 protein levels on Gal-
3 expression. (A) Western blot analysis, using antibodies to HIPK2
and Gal-3, performed on TCE obtained from PTC-derived K1 cell line
stably transfected with pSUPER.retro control vectors (ctr) and pSUPER-
HIPK2 interfering construct (HIPK2i). (B) Inverted images of agarose
gels showing semiquantitative RT-PCR analyses of HIPK2 and Gal-3
gene expression performed on total RNA extracted from K1 cells
described in (A). (C) Western blot analysis of HIPK2 and Gal-3 in K1 cell
transiently transfected with control vector pCMV-FLAG (Flag) and with
pCMV-FLAG-HIPK2 (Flag-HIPK2) expression construct. (D) Inverted
images of agarose gels showing semiquantitative RT-PCR analyses of
HIPK2 and Gal-3 gene expression performed on total RNA extracted
from K1 cells described in (C). (E) Western blot analysis of HIPK2,
p53Ser46, total p53 and Gal-3 in K1 cell transiently transfected with the
kinase-dead pEGFP-HIPK2
K221R (GFP-HIPK2
K221R) and the wild type
pEGFP-HIPK2 (GFP-HIPK2) HIPK2 expression constructs. Western blot
experiments were normalized using b-actin protein expression while
the 18S gene was amplified as control for semiquantitative RT-PCR
analyses.
doi:10.1371/journal.pone.0020665.g005
HIPK2 Loss in Thyroid Tumours
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e20665RNA present in each reaction. Sequences of the primers specific
for both 18S and Gal-3 were previously reported [10]. PCR
products were visualized on a 2% agarose gel after ethidium
bromide staining. Three independent experiments were performed
for each sample. The intensities of the bands on gels were
measured by densitometry, using the NIH ImageJ software
(version 1.32j).
Real Time RT-PCR analysis
The mRNA expression levels of HIPK2 were analysed in thyroid
samples of the group B. FH and PTC lesions were analysed and
compared to a pool obtained from the 10 NTT samples, using the
TaqMan Gene Expression Assay No. Hs00179759_m1 (Applied
Biosystems, Foster City, CA, USA), according to a previously
described methodology [41]. The results were normalized with
those obtained amplifying the endogenous control 18S, assay
Hs99999901 s1 (Applied Biosystems). The results were calculated
using the 2
2DDCT method [42] and the mean expression of the
NTT pool as calibrator. Results were statistically evaluated using
Student’s t-test.
Immuno-Laser capture microdissection and LOH analysis
Slides obtained from thyroid tissue specimens of group C were
immunostained for Gal-3, as previously reported, and counter-
stained with haematoxylin and eosin. Thyroid follicular cells were
microdissected using the Pix Cell II Laser Capture Microscope
(Arcturus Engineering) as described [25]. For each slide, at least
two separate caps, one with Gal-3-positive tumour cells and one
with matching, peri-tumoural (Gal-3-negative) follicular cells were
obtained. DNA extracted from microdissected cells was amplified
by PCR in the presence of specific primers flanking the sequence
of the microsatellite markers D7S2468 and D7S6440. The first
marker is located at 7q32-34 (cytogenetic localization 150.3 cM),
in the same region where the human HIPK2 gene has been
mapped, and has been chosen according to the Radiation Hybrid,
Genebrifge4, Stanford G3 and Genethon indications and to
maximal heterozygosity [43]. The second marker is a newly
identified microsatellite internal to the HIPK2 gene (Accession
Number # AY563634). This marker, that we named D7S6440,
consists of a di-nucleotide repeat (CA) and its sequence variability
in the general population has been recently calculated (Sciacchi-
tano, unpublished results). All the oligonucleotide primers used in
the study were synthesized and purchased from MWG Biotech
and their sequences are available upon request. LOH analysis was
conducted as previously described [25]. Reproducibility of each
LOH was confirmed by at least two independent experiments.
The FAL index was calculated as previously reported [25].
Cell culture and plasmid constructs
The human PTC-derived K1 cells were purchased from ECACC
(Salisbury, United Kingdom) and grown in DMEM:Ham’s F12
(Lonza Walkersville, Inc. Walkersville, MD):MCDB-105 (Sigma
Saint Louis, Missouri) (2:1:1) medium added with 10% FBS, and
supplemented with 2 mM glutamine and 100 U/ml penicillin and
streptomycin mix (Lonza).
RNAi of HIPK2 expression was obtained in K1 cells by stable
transfection of pSUPERretro and pSUPER-HIPK2 constructs
[10].
Overexpression of the wild type and mutant HIPK2
K221R was
obtained by transient tranfection of K1 cells using the following
constructs: pCMV-FLAG, pCMV-FLAG-HIPK2, pEGFP-HIPK2
and pEGFP-HIPK2 K221R [10]. It should be noted that K1 are a
suitableandrepresentative WDTCcellularmodel.They,infact,are
characterized by overexpression of Gal-3 and very low, even if
detectable, levels of HIPK2.
Transfections were performed using Lipofectamine (Invitrogen)
according to manufacturer’s instructions. Selection of stably
transfected cells was performed by treatment with puromicin at
the concentration of 2 mg/ml (Sigma).
Western Blot analysis
Total cell extracts (TCEs) were obtained as previously described
[41]. Aliquots of TCEs (30–70 mg) were separated through 5%–
10% SDS-PAGE and blotted onto nitrocellulose membrane (BIO-
RAD). The following antibodies were used in immunoblotting:
rabbit anti-HIPK2 antiserum (kindly provided by L. Schmitz),
purified rat mAb anti-Gal-3 antibody (Mabtech AB, Nacka
Strand, Sweden), mouse mAb anti-p53 (Santa Cruz), mouse
mAb anti-p53Ser46 (Cell Signaling Technology) and mouse mAb
anti-b-actin (Sigma), and HRP-conjugated anti-rabbit, anti-rat or
anti-mouse, antibodies (Sigma). Immunoreactivity was detected
using ECL kit (Amersham Corporation). Densitometric analysis of
the intensity of the bands was performed using the software NIH
ImageJ (version 1.32j).
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